APPLICATION
ANDA203844
TYPE
ANDA
ORIGINAL APPROVAL
2017-02-13
LATEST ACTION
2019-07-23
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription
Products
RIVASTIGMINE TARTRATEPrescription
RIVASTIGMINE TARTRATE EQ 6MG BASE · CAPSULE · ORAL
RIVASTIGMINE TARTRATEPrescription
RIVASTIGMINE TARTRATE EQ 3MG BASE · CAPSULE · ORAL
RIVASTIGMINE TARTRATEPrescription
RIVASTIGMINE TARTRATE EQ 4.5MG BASE · CAPSULE · ORAL
RIVASTIGMINE TARTRATEPrescription
RIVASTIGMINE TARTRATE EQ 1.5MG BASE · CAPSULE · ORAL
Approval history
2019-07-23Labeling · Supplement 3 · standardAP
2019-07-23Labeling · Supplement 2 · standardAP
2017-02-13UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.